Pediatric Formulations Of Oral Oncologics Sought By FDA
FDA is trying to encourage developers of oral cancer agents to create pediatric formulations as part of the development process
You may also be interested in...
Legislation restoring FDA's authority to require drug sponsors to conduct trials in children would sunset at the same time as the pediatric exclusivity incentive program under a bill adopted by the Senate July 23
AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005
GlaxoSmithKline's Purinethol (mercaptopurine) should include labeling recommending use of pharmacogenetic testing to guide dosing, the Clinical Pharmacology Subcommittee of FDA's Pharmaceutical Science Advisory Committee concluded at its Oct. 23 meeting